Investor Relations :: Rigel Pharmaceuticals, Inc. (RIGL)
Dec 7, 2025 · Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune …
Who We Are :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and …
Management Team :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and …
Rigel Reports First Quarter 2025 Financial Results and Provides ...
May 6, 2025 · Rigel continues to advance its Phase 1b clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of R289 in patients with relapsed or refractory (R/R) lower …
News & Events :: Rigel Pharmaceuticals, Inc. (RIGL)
Dec 8, 2025 · Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635 (c) (4) Corporate Presentation January 2026 Recent Events View All Events
Press Releases :: Rigel Pharmaceuticals, Inc. (RIGL)
Dec 7, 2025 · Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition Nov 26, 2025 8:05am …
Join Our Team :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and …
Rigel Announces Poster Presentations at the 2025 ASCO Annual …
May 22, 2025 · Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients …
Rigel Announces R289 Granted Orphan Drug Designation by the FDA …
Jan 9, 2025 · Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients …
Rigel Reports Second Quarter 2025 Financial Results and Provides ...
Aug 5, 2025 · Total revenue and net income are inclusive of $40 million in non-cash contract revenue related to Rigel's agreement with Lilly Conference call and webcast scheduled today at 4:30 p.m. …